Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

← catalyst calendar

NCT07489066 · readout in 709 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

120estimated

Sites

Countries

China, Israel, Puerto Rico +2

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-30

actual

When the study began enrolling

Primary completion

2028-07-29

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-07-30

estimated

The whole study's end, after follow-up

First posted

2026-03-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-17

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Carcinoma
Non-Small-Cell Lung
Lung Cancer (NSCLC)
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung (NSCLC)
Lung Disease
Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer, Non-squamous
Non-small Cell Lung Cancer, Squamous

Interventions

Biological: PF-08634404 — also filed as SSGJ-707
Drug: Chemotherapy Regimen 1
Drug: Chemotherapy Regimen 2

Primary outcomes

what the primary-completion date above is the date OF

Number of Participants With Adverse Events (AEs)

measured Through 90 days after the last dose of study intervention (Part A only: or 90 days after surgery, whichever is later)

Part A: Surgical Feasibility Rate

measured Up to approximately 6 months after first dose

Part A: Pathological Complete Response (pCR) rate per International Association for the Study of Lung Cancer (IASLC) guidelines as assessed by central pathology review

measured Up to approximately 6 months after first dose

Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed